Navigation Links
Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
Date:2/22/2010

31, 2008.

Recent Highlights:

  • Submitted an amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) for which the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010.
  • Raised $409.5 million in net proceeds through a common stock offering in the fourth quarter 2009, bringing the total net funds raised for the year to approximately $630 million, allowing the Company to accelerate the build out of the Atlanta, Georgia and Orange County, California commercial manufacturing facilities, which we expect will become operational in mid-2011.
  • Hired Hans Bishop as chief operating officer. Hans was most recently president of the specialty medicine business at Bayer and executive vice president of Bayer Healthcare LLC.
  • Elected Ian Clark, chief executive officer and head of North American commercial operations at Genentech, and Pedro Granadillo, former senior vice president of global manufacturing and human resources at Eli Lilly & Company, to Board of Directors.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
2. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
5. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
7. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
8. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
11. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Boston Scientific Corporation (NYSE: BSX ) ... Healthcare Conference on September 17, in New York ... executive officer, and Dan Brennan , executive vice president ... and answer session regarding the company with the host analyst ... webcast of the question and answer session will be available ...
(Date:9/2/2015)... 2015  MGC Diagnostics Corporation (NasdaqCM: MGCD), a global ... discuss its financial results for the third quarter of ... be at 4:30 p.m. ET on Thursday, September 10, ... third quarter of fiscal 2015 after the markets close ... can dial (877) 317-6789 or (412) 317-6789 to access ...
(Date:9/2/2015)... Delcath Systems, Inc. (NASDAQ: DCTH ), ... oncology with an emphasis on the treatment of primary ... participate in the upcoming 17 th Annual Rodman ... at the St. Regis Hotel in New York City.  ... and Chief Executive Officer, will present a corporate overview ...
Breaking Medicine Technology:Boston Scientific To Participate In 2015 Morgan Stanley Global Healthcare Conference 2MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2Delcath To Present At The 17th Annual Rodman & Renshaw Conference 2Delcath To Present At The 17th Annual Rodman & Renshaw Conference 3
... DIEGO, Dec. 18 Ambrx Inc. today announced ... with Merck & Co. Inc. to,develop a novel ... Factor 21 (FGF-21) for the treatment of type ... The collaboration utilizes Ambrx,s proprietary protein technology,ReCODE(TM), ...
... Epeius Biotechnologies,Corporation announced today that the company ... Rexin-G(R) from the Philippine Bureau of Food ... lead product as a safe,and effective treatment ... as a tumor-targeted anticancer agent, that actively ...
Cached Medicine Technology:Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc. 2ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer 2ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer 3
(Date:9/2/2015)... ... September 02, 2015 , ... ... patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions ... Series. The series enables pharmaceutical researchers to participate in interactive programs in ...
(Date:9/2/2015)... ... 02, 2015 , ... RxNT , an innovative software ... enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone app marks ... leader in health technology, RxNT was one of the first to build an ...
(Date:9/2/2015)... Covington, LA (PRWEB) , ... September 02, 2015 ... ... new President/CEO and Regulatory Affairs Officer following the departure of Kristen Dietz, former ... Medical Officer of Healtec® released the following statement welcoming Mr. Salot: “ Stanley ...
(Date:9/2/2015)... ... 02, 2015 , ... Splashtop Inc., the worldwide leader in ... mirroring and extending product line -- Splashtop Wired XDisplay . Complementing ... setting, the new Splashtop Wired XDisplay delivers enhanced performance and reliability for users ...
(Date:9/2/2015)... ... September 02, 2015 , ... Care Providers and their ... documents that include EOBs, payments, and payment related documents. AD-EOB A/R helps them ... reconcile their billing, with one efficient process and interface,“ stated Rich Caproni, AliusDoc’s ...
Breaking Medicine News(10 mins):Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:Healtec® Announces Executive Leadership Change 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2
... A North Carolina team of doctors, nurses, hospitals and ... way to provide faster, more effective treatment for heart ... or fancy new equipment. But it does require competitors ... to move treatment forward empowering emergency services personnel ...
... condition, which is symptomless, can lead to heart attack ... More American women are suffering from asymptomatic peripheral artery ... risk for heart attack and stroke, a new study ... of an increase in common cardiovascular risk factors, namely ...
... from union benefit funds,Union coalition says Rite Aid wants union money, but ... ... They are telling conference attendees: Trust Rite Aid? Think Twice!, ... pharmacy benefits management company (Rite Aid,Solutions) at the International Foundation Employee Benefits ...
... TARRYTOWN, N.Y., Nov. 3 EpiCept Corporation,(Nasdaq and OMX ... a,conference call to discuss third quarter 2007 results and ... 8:30 a.m. EST. EpiCept,will release results for the three ... EST on Monday, November 5, 2007. (Logo: ...
... is disappointed with today,s ruling and we intend to ... at issue was the result of,highly competitive conditions in ... ruling on liability is thus profoundly,anti- competitive. AstraZeneca ... drugs and we firmly believe that we have acted ...
... Mexican Red Cross for Flood,Relief, WASHINGTON, Nov. 2 ... to provide $50,000 to the Mexican Red Cross to,assist ... than,800,000 people. Unusually heavy rains caused rivers to overflow ... was already waterlogged,after Hurricanes Dean and Felix., "Thousands ...
Cached Medicine News:Health News:RACE: a statewide model of better, faster heart attack care 2Health News:RACE: a statewide model of better, faster heart attack care 3Health News:Peripheral Artery Disease Up Sharply Among U.S. Women 2Health News:Peripheral Artery Disease Up Sharply Among U.S. Women 3Health News:Rite Aid's Fledgling Benefits Management Firm Hits Turbulence at Employee Benefits Conference in Anaheim 2Health News:EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007 2Health News:EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007 3Health News:Sister Red Cross Societies Help Each Other 2
... contemporary reading card was designed by James ... of near point exercises including words, numbers ... 20/260, 20/200, 20/100, 20/65, 20/50, 20/40, 20/30, ... reading in English and metric, Jaeger, point ...
Standard reading test. "walked regularly..."...
Standard reading test. "Children should be..."...
Near PT test card/Tumbling E, tumbling hands 5 1/2" X 8"....
Medicine Products: